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Alterations in non-adrenergic, non-cholinergic (NANC) function may contribute to nocturnal asthma. We have 
attempted to clarify the importance of the NANC system in the circadian variation in airway calibre in mild 
asthmatics and nocturnal asthmatics. 
NANC function in the human airway was studied at 0400 and 1600 hours in 12 nocturnal asthmatics and 
12 mild asthmatics by measuring oscillatory resistance (Ros) following capsaicin inhalation. Measurements 
were made after combined /I- and atropinic blockade in the mild asthmatics but after atropinic blockade 
alone in the nocturnal asthmatics, in whom P-blockade is contraindicated. To determine whether P-blockade 
influences NANC bronchodilatation, we also studied 12 normal subjects with and without P-blockade at 
1600 hours only. 
The mild asthmatics showed differing (FO.007) resistance changes l-3 min after capsaicin at 1600 hours (fall in 
Ros+ l%, CI - 2% to 3%) from that at 0400 hours ( - 4%, CI - 8% to - 1%) but the nocturnal asthmatics showed 
no significant difference in response to capsaicin at the two times (fall in Ros: 1600 hours - 9%, CI - 15% to - 3%; 
0400 hours - 3%, - 7% to 1%). The normal subjects showed greater (P=O.OOOl) bronchodilatation l-3 min after 
capsaicin following atropine plus propranolol ( - 7%, - 11% to - 3%) than after atropine alone (- 2%, - 6% to 
2%), supporting interaction between the ,&sympathetic and NANC systems in the human airway, NANC 
bronchodilatation being inhibited by P-sympathetic activity. 
Our observations confirm circadian variation in NANC function in mild asthmatics and suggest interaction 
between the /3-adrenergic and the NANC bronchodilating system in the normal human airway. 
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Introduction 
Overnight bronchoconstriction results in intermittent noc- 
turnal cough, wheeze or breathlessness in over 85% of 
asthmatics. These symptoms are due to nocturnal airway 
narrowing, a major factor in which is altered autonomic 
bronchomotor tone. Nocturnal airway narrowing is 
associated with increased parasympathetic cholinergic 
activity (1). The only other efferent nervous system 
known to act directly on human bronchial smooth muscle is 
the non-adrenergic, non-cholinergic (NANC) system (2), 
activation of which may produce initial transient broncho- 
constriction (3) followed by more sustained bronchodilata- 
tion (4,5) probably mediated, at least in part, by nitric 
oxide (6,7). 
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We have recently reported that inhibition of the NANC 
bronchodilating (INANC) system may be important in the 
pathogenesis of overnight airway narrowing, finding that 
iNANC bronchodilatation after capsaicin inhalation was 
significantly greater at 1600 hours than at 0400 hours (8). 
As NANC function is conventionally tested following 
combined muscarinic and /3-adrenergic blockade, that 
study (8) was performed in normal subjects and 
patients with mild asthma and not in patients with 
nocturnal asthma in whom P-blockade is contraindicated 
because of the severity of their asthma. Therefore, we 
have now assessed the variation between 0400 hours 
and 1600 hours in the airways response to inhaled 
capsaicin in patients with nocturnal asthma following 
atropinic blockade, without P-blockade, and compared 
their response with that in patients with mild asthma 
who could be studied following both atropinic and 
P-blockade. As possible interaction between the 
P-sympathetic and iNANC systems has not been studied, 
we have also studied the response of the airways to 
capsaicin inhalation after atropinic blockade with and 
without the addition of B-blockade in normal subjects, to 
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TABLE 1. Characteristics of asthmatics 
Mean FEV Fall in 
Subject Age (% predicted PEFR overnight 
No. Sex (years) Atopy Smoker at 0400 hours) (%I Treatment 
Mild asthmatics 
1 M 67 
2 M 54 
3 F 26 
4 M 26 
5 F 28 
6 M 34 
7 M 52 
8 F 22 
9 F 33 
10 F 40 
11 M 29 
12 F 21 
Nocturnal asthmatics 
1 F 58 
2 F 60 
3 F 43 
4 M 48 
5 F 42 
6 M 25 
7 M 24 
8 M 26 
9 M 65 
10 F 17 
11 F 22 
12 F 26 
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S:333 f 108 
Mean f SEM. 
/?, P-agonist; S, inhaled steroid, dose (ug day- I); T, oral theophylline. 
aid interpretation of the studies performed in the absence 
of a-blockade. 
Methods 
All subjects gave written informed consent to participate in 
the study which had been approved by the local Ethical 
Advisory Committee. 
SUBJECTS 
Subject characteristics are outlined in Table 1. 
NOCTURNAL ASTHMATICS 
Nocturnal asthma was defined as a mean PEFR fall of at 
least 15% overnight in a subject reporting at least two 
nocturnal awakenings due to asthma per week during a 2 
week run-in period. We studied 12 nocturnal asthmatics 
(five males, eight atopic), mean age 38 years, range 17-65 
years, with a mean FEV, at 0400 hours of 73% f 6% (SEM) 
predicted. The mean percentage fall in PEFR overnight was 
25% f 4% @EM). 
MILD, ASTHMATICS 
Mild asthma was defined as a mean FEV, at 0400 hours of 
>80% predicted, with no nocturnal awakenings due to 
asthma and a mean overnight PEFR change of < 15% 
during a 2 week run-in period. Twelve mild asthmatics were 
studied (six males, eight atopics), mean age 36 years, range 
21-67 years, with a mean FEV, at 0400 hours of 90% f 3% 
@EM) predicted. All had histories and respiratory function 
evidence of intermittent reversible airflow obstruction. The 
mean percentage fall in PEFR overnight was 8% & 3% 
(SEM). 
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NORMAL SUBJECTS 
Twelve normal subjects (eight males, two atopic) aged 
24-41 years were studied. None had a history of respiratory 
illness and all had normal respiratory function. 
MEDICATION 
All patients continued on their normal anti-asthma medi- 
cation but withheld all bronchodilators for 6 h prior to each 
study. 
MEASUREMENT OF RESPIRATORY RESISTANCE 
The respiratory resistance (Ros) was measured by a forced- 
oscillation technique. The subject was seated with cheeks 
supported by the palms of the hands and breathed normally 
through a mouthpiece connected to an oscillometer 
(Sirengost FO 5, Siemens, Erlangen, Germany), which was 
linked to a pneumotachograph. All Ros measurements were 
made at zero flow. 
CAPSAICIN CHALLENGE 
Capsaicin 1 mg (Sigma Chemicals, Poole, U.K.) was 
dissolved in 10 ml 10% ethanol in 0.9% saline (by volume), 
so the final concentration was 3.28 x 1O-4 mol l- ‘. The 
diluent (10 ml 10% ethanol in 0.9% saline) was used as 
placebo. Both solutions were given in a single-blind, rand- 
omized, crossover fashion through a nebulizer controlled 
by a dosimeter (Spira Elektroz 2, Respiratory Care Centre, 
Hameenlinna, Finland) set to nebulize for 0.7 s at a pres- 
sure of 14 lbf in - * (1 bar or 10’ Pa). The nebulizer had an 
output of 7.1 ,LL~ per breath and the mean mass aerodynamic 
diameter of the particles generated was 1.6 pm. One breath 
from the nebulizer produced 2 nmol of capsaicin. Capsaicin 
or ethanol-saline could not be given in a double-blind 
fashion because capsaicin caused transient cough (‘5 s) in 
all subjects. The subjects were not informed of the order of 
administration of the two agents. Ros was recorded for the 
first 20 s, over the period l-5 min and for a further minute 
at 9 min 30 s after each inhalation. This last value was used 
as a baseline measurement for inhalation of the crossover 
solution (diluent or capsaicin). 
STUDY DESIGN 
Nocturnal vs. Mild Asthmatics 
Subjects were studied twice at least 36 h apart, once at 0400 
hours and once at 1600 hours, the order being randomized 
using random number tables to eliminate any order effect. 
After baseline measurements of pulse and Ros, all were 
given intravenous atropine (0.03 mg kg- ’ over 3 min) to 
produce parasympathetic blockade (9). When maximum 
heart rate had been reached, intravenous propranolol 
(0.25 mg kg- ‘) was given to the mild asthmatics. After 
5 min, the subjects inhaled one breath of either capsaicin or 
diluent and Ros was measured as described above. At 
10 min 30 s, diluent or capsaicin was inhaled. 
Study of Effect of p-blockade 
Twelve normal subjects were studied on two occasions at 
1600 hours, the time iNANC bronchodilation is demonstra- 
ble (8). In a randomized double-blind study, the subjects 
received either intravenous atropine (0.03 mg kg ~ ’ over 
3 min alone or intravenous atropine plus propranolol 
(0.25 mg kg- ‘). Thereafter, capsaicin and diluent were 
inhaled in a randomized order and Ros was measured as 
described above. 
Statistical Analysis 
The aim was to compare the extent of bronchodilatation 
after capsaicin inhalation on the two occasions. This bron- 
chodilatation follows transient (< 1 min) bronchoconstric- 
tion (3) and lasts no longer than 3 min (5,lO). Thus, as 
before (8) our a priori analysis was the comparison of the 
changes in Ros averaged over the period l-3 min after 
capsaicin inhalation on the two occasions. Analysis of 
variance was used for comparison of paired observations. 
Intergroup comparisons were analysed using unpaired t 
tests. 
Results 
MILD AND NOCTURNAL ASTHMATICS 
Mild Asthmatics 
Oscillatory resistance was the same before capsaicin at the 
two times of day (Table 2). The immediate increase in Ros 
after capsaicin inhalation was similar for the morning and 
afternoon experiments (Fig. 1). However, there was a 
significant difference in the response to capsaicin seen over 
the period l-3 min after inhalation between the time points 
(PzO.07, Fig. 1) with a change in Ros averaged over 
l-3 min at 1600 hours of - 1% (SEM 1%) compared with a 
rise of +4% (SEM 2%) at 0400 hours. Time of day did not 
influence Ros changes after diluent inhalation. 
Nocturnal Asfhmafics 
Oscillatory resistance was significantly higher before 
capsaicin at 0400 hours than at 1600 hours (Table 2). 
There was no difference in the immediate increase in Ros 
after capsaicin inhalation at the two time points (Fig. 2). 
There was also no difference in Ros measured over 1-3 min 
after capsaicin inhalation at the two times of day: mean 
increase in Ros over l-3 min 3% (SEM 2%) at 0400 hours 
and 9% (SEM 3%) at 1600 hours (P=O.29, Fig. 2). Time of 
day did not influence Ros changes after diluent inhalation. 
P-BLOCKADE STUDY 
Baseline airway resistance (Ros) was similar following 
atropine alone or when atropine plus propranolol was used 
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TABLE 2. Baseline measurements 
Variable 
Mild asthmatics Severe asthmatics Normal subjects 
0400 hours 1600 hours 0400 hours 1600 hours Atropine Atropine+Propranolol 
Baseline Ros before 2.8 f 0.2 2.4 f 0.2* 5.5 zt 0.8 4.0 * 0.5* 2.1 0.2 f 2.0 f 0.2 
atropine f propranolol 
(cmH,Ol-’ s-l) 
Percentage fall in Ros after 18&3 21 f3 32k.5 20 f 5* 15&6 15*5 
atropine f propranolol 
Ros before capsaicin 2.3 f 0.2 2.0 f 0.1 4.1 f 0.4 3.3 + 0.3* 1.7kO.l 1.7ztO.l 
(cmH,Ol-’ s-l) 
Mean f SEM. 
*P<O.O5 KS. same group in preceding column. 
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FIG. 1. Change in oscillatory resistance (Ros) at 0400 FIG. 2. Change in oscillatory resistance (Ros) at 0400 
hours (0) and 1600 hours (0) after inhalation of capsai- hours (0) and 1600 hours (0) after inhalation of capsai- 
tin in patients with mild asthma. P=O.O07 for the differ- tin in nocturnal asthmatics. There is no difference 
ence between curves average over l-3 min. between curves averaged over l-3 min (P=O.29). 
(Table 2). The immediate increase in Ros after capsaicin 
inhalation was similar (P=O.ll) during the first 10 s after 
capsaicin inhalation on the two occasions (Fig. 3). How- 
ever, the decrease in Ros thereafter was significantly greater 
following atropine and propranolol compared with atro- 
pine alone [mean decrease in Ros l-3 min after capsaicin: 
7% * 2% (SEM) after atropine plus propranolol; - 2% * 2% 
(SEM) after atropine alone; P=O.OOOl, Fig. 31. 
Discussion 
The major finding in this study is of interaction between the 
p-sympathetic and NANC systems in the human airway. 
This study also confirms our previous observation of a 
difference in the response of mild asthmatics between 0400 
and 1600 hours l-3 min after capsaicin inhalation (S), 
compatible with inhibition of NANC bronchodilator func- 
tion at 0400 hours. However, in contrast to our current and 
previous (8) findings in patients with mild asthma and 
P = 0.29 
normal subjects, we did not find any difference between the 
responses to capsaicin at the two times of day in the 
patients with nocturnal asthma who did not bronchodilate 
at any stage after capsaicin inhalation. 
There are several possible explanations for the latter 
observation. Firstly, iNANC bronchodilating activity may 
be impaired in patients with severe asthma. Although 
NANC mediated bronchodilatation has been found in 
patients with mild asthma (8,10), previous studies have been 
in patients with less severe asthma than those we have 
studied. Secondly, the patients with nocturnal asthma were 
on more medication than the milder asthmatics [mean daily 
dose of inhaled steroid was 917 f (SEM) pg VS. 333 f 108 
(SEM) pug] and this might perhaps alter the response to 
capsaicin, although none of the drugs they were taking is 
known to have such an effect. Thirdly, there may be no 
circadian variation in iNANC function in the airways of 
patients with nocturnal asthma. This is possible, but we 
believe unlikely, as there is variation in iNANC function 
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FIG. 3. Change in oscillatory resistance (Ros) at 1600 
hours in the normal subjects after atropine+propranolol 
(0) and after atropine alone (0). P=O.OOOl for the differ- 
ence between curves average l-3 min. 
through the day in both mild asthmatics-confirmed in 
this study - and normal subjects (8). In addition, the linear 
and continuous relationship between bronchial reactivity 
and circadian variation in peak flow rates which encom- 
passes not only patients with mild and nocturnal asthma 
but also normal subjects (11) suggests that similar mecha- 
nisms may cause the overnight bronchoconstriction in all 
groups. Fourthly, the lack of P-blockade in the patients 
with nocturnal asthma may explain or contribute to the 
failure to demonstrate any temporal differences in NANC 
function. 
This last explanation is in keeping with the results of the 
study in normal subjects which demonstrated that 
capsaicin-induced bronchodilatation was only evident after 
pretreatment with ,&blocking agents. Previous studies have 
shown interaction between the eNANC and adrenergic 
systems (12,13). There is modulation of eNANC action by 
selective a-,-adrenoceptor agonists acting via prejunctional 
inhibitory a-,-adrenoceptors (12). There is similar pre- 
synaptic inhibitory a-,-adrenoceptor action on vagal 
cholinergic bronchoconstriction (14). &Agonists inhibit 
eNANC activity in the in vitro guinea pig trachea (13). We, 
however, found that P-blockade made no difference to the 
early bronchoconstriction after capsaicin - which some, but 
not all (3) believe results from eNANC action-although 
there was a trend (P=O.ll) for the bronchoconstriction to 
be less without b-blockade. Interactions between the 
iNANC system and other limbs of the autonomic nervous 
system have been less studied. Recent evidence suggests 
that there is no presynaptic modulatory a-adrenoceptor 
control of iNANC function (13,15). No mention has, 
however, been made of any direct interaction between the 
fl-adrenergic system and the iNANC system. Our study 
suggests that there is indeed interaction between NANC 
inhibitory nerves and the /3-adrenergic nervous system in 
the human airway. The site of this interaction is unclear and 
the study was not designed to localize them. Indeed, the 
p-blockade could be having an effect either at the neural 
level or by blocking endocrine catechol effects. 
We are aware that there is some evidence in humans that 
bronchodilatation can result following inhalation of capsai- 
tin in subjects who are not P-blocked (10). However, these 
subjects had been prebronchoconstricted with leukotriene 
D, whereas our subjects were not prebronchoconstricted. 
Similarly, Micoud et al. (16) reported a reflex decrease in 
histamine-induced bronchoconstriction in both asthmatic 
patients and in normal subjects which was modulated by 
the NANC nervous system. Both groups of subjects were 
prebronchoconstricted with histamine but not b-blocked. 
These results suggest that either prior P-blockade or 
prior bronchoconstriction is necessary for NANC bron- 
chodilatation to be detected by capsaicin inhalation in 
humans. The precise role of any interaction between the 
P-adrenergic and the NANC inhibitory nerves requires 
further clarification. 
The effect of P-blockade in normal subjects is not caused 
by the induction of more marked bronchoconstriction prior 
to capsaicin inhalation as airway resistance was unchanged 
by infusion of propranolol [1.7 f 0.1 (SEM) before pro- 
pranolol and 1.7 & 0.1 (SEM) cmH,O 1 - ’ s - i after pro- 
pranolol]. This is in agreement with previous studies which 
found that P-blockade has no effect on airway calibre in 
normal subjects (17,18). 
The magnitudes of the difference in changes in Ros in this 
study are small. However, they are consistent and statisti- 
cally significant and the patterns observed in the mild 
asthmatics and in the normal subjects are consistent with 
our previous observations (8). We thus feel that the differ- 
ences observed are real. We chose not to examine iNANC 
function following prebronchoconstriction with leukotrine 
D, (4) as others have done because we felt that this would 
introduce another element of between-subject variability, 
making interpretation of our quantitative data very diffi- 
cult. As we had previously shown that iNANC effects 
were demonstrable at 1600 hours in normal subjects 
without prebronchoconstriction, we felt that this was the 
appropriate methodology to use. 
This study therefore shows that there is interaction 
between the P-adrenergic system and the NANC bron- 
chodilating system in the normal human airway. The 
NANC system is the only direct neural bronchodilating 
pathway in the human airway, and our data indicate that 
P-adrenergic activity inhibits the iNANC response to cap- 
saicin. It remains to be seen whether this could be related to 
the reported deleterious effects of p-agonist drugs on the 
control of asthma (19,20). 
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